头像

Jianjun Cheng, PhDAssociate Professor

Tel: 021-20685237

Email: chengjj@shanghaitech.edu.cn

Fax:

Add:

Faculty KMS Profile

中文信息English
Medicinal Chemistry and Drug Discovery

Principal investigator

Name:

Jianjun ChengAssociate Professor , PhD, Associate Professor

Position:

Affiliation:

Honor:

Education Background:
  • 2001/09-2005/06, Shandong University, BS
  • 2005/09-2010/07, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Ph.D.
Working Experience:
  • 2010/07-2013/10, Shanghai Huilun Life Sciences & Technology, Senior Scientist
  • 2013/11-2016/03, University of Illinois at Chicago, Postdoctoral Research Associate
  • 2016/03-2022/06, ShanghaiTech University, iHuman Institute, Principal Investigator
  • 2022/07-present, ShanghaiTech University, School of Life Science and Technology/iHuman Institute, Assistant Professor (TENURE-TRACK)

Group Introduction

Research Area:
GPCR-targeted drug discovery
Research Interests:

The research of our group is focused on GPCR-targeted medicinal chemistry and drug discovery. We leverage the knowledge on the structures and functions of G protein-coupled receptors (GPCRs) for the design of novel drug-like compounds with therapeutic potential. A major focus is targeting aminergic and orphan GPCRs for the design of next-generation therapeutics for the treatment of neuropsychiatric disorders, in particular, depression and schizophrenia. From a medicinal chemistry perspective, our research goal is the design of novel drug-like compounds by addressing the following three scientific challenges in GPCR drug discovery: (1) Structure-based design of subtype-selective GPCR modulators; (2) Rational design of “biased” GPCR ligands that are functionally selective for a specific signaling pathway; (3) Rational design of GPCR ligands with desired polypharmacological profiles. Our research is dedicated to developing innovative therapeutics that address critical unmet needs in neuropsychiatric disorder treatment.

Group Website:

Research Achievement

1. Structure-based discovery of non-hallucinogenic psychedelic analog IHCH-7086 as a novel antidepressant drug candidate (Science 2022).

2. Structure-based discovery of highly selective dopamine D2 receptor partial agonist IHCH-7041 as a novel preclinical anti-schizophrenia drug candidate (Nature Neuroscience 2022, cover story).

3. PCPMA-based highly selective serotonin 2C agonists with anti-schizophrenia effects (J Med Chem 2015; 2016a; 2016b); highly selective dopamine D3 ligands (J Med Chem 2020); and dopamine D2 partial agonists with anti-schizophrenia effects (J Med Chem 2021).

4. Discovery of dual-acting tumor immunotherapeutics targeting the adenosine A2a receptor and histone deacetylases (J Med Chem 2021; Eur J Med Chem 2022).

Representative Publications (*First Author, # Corresponding Author)

Monograph

Patent

Funding

Awards

Research Achievement

Group Member and Photo

返回原图
/